Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10187484
• 负责人: SCOTT A SMALL
• 金额: $ 314.81万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10187484
• 关键词: Address; Advisory Committees; Alzheimer' s Disease; Awareness; Biological; Biological Markers; Cell physiology; Cholesterol Homeostasis; Clinical; Clinical Investigator; Clinical Trials; Collaborations; Committee Members; Communities; Data; Discipline; Disease; Early Diagnosis; Enrollment; Environment; Fostering; Genes; Genetic; Genomics; Goals; Immune response; Infrastructure; Institution; Intervention; Learning Module; Mission; Nerve Degeneration; Observational Study; Participant; Pathogenesis; Pathogenicity; Pathology; Pathway interactions; Patient Care; Patient Recruitments; Patients; Pharmaceutical Preparations; Prevention; Research; Research Infrastructure; Research Personnel; Resources; Therapeutic Trials; Time; Training; United States National Institutes of Health; Universities; Vision; Work; amyloid pathology; base; career; community organizations; data management; education research; interdisciplinary collaboration; interest; neuroimaging; neuroimmunology; neuropathology; outreach; patient outreach; phenomenological models; prevent; programs; ranpirnase; recruit; success; tau Proteins; tool; trafficking; translational scientist

OVERALL PROJECT SUMMARY/ABSTRACT This is a new application for a P30 ADRC at Columbia University, continuing the tradition of our previous P50 ADRC that has existed at Columbia since 1989. Building off our prior accomplishments, the overall objective of the new ADRC is to support and promote cutting-edge research on Alzheimer’s disease (AD) and related disorders, both locally in our extensive campus and more globally with other institutions and national consortia. Subsumed within this objective the Center will have a more focused theme. The theme, focusing on ‘biological pathways’ implicated in AD pathogenesis, was decided on after internal deliberations, discussions with our External Advisory Committee members, and with NIH project officers. As reviewed throughout the proposal, we believe that this broad theme has many advantages. It will strengthen the overall objective by better serving our local community of basic, translational, and clinical investigators; and will generate new tools and resources that we will share with other institutions, consortia, and organizations. Additionally, the theme will allow each core to have both general aims that harmonize with other ADRCs and consortia, and theme-guided aims that emerge from our local strengths. As reviewed below, the theme will allow cores to synergize and work together in creating a research infrastructure that relate to the clinical phenomenology, neuropathology, neuroimaging, and genomics of AD. Since its inception 30 years ago, the ADRC at Columbia has established an elaborate infrastructure for research, fostered interdisciplinary collaborations, established a rich training environment, and promoted outreach and patient recruitment. At the same time the Center has become an active participant in a more global network comprised of other institutions, national consortia, and community organizations. During the many cycles of the P50 ADRC, the Center has attained most of its goals, as evidenced, for example, by the breadth of its scientific findings and by its high ranking of enrolled and active patients. In this proposal for a new P30 ADRC we will build off of these prior accomplishments moving forward, and will be motivated by two general goals. The first goal is to continue, as in previous cycles, to foster all research on AD and related disorders, while the second goal is to support the theme. We propose to achieve these goals through our well-integrated cores, which collectively establishes an infrastructure that generates a rich array of resources, biospecimens, and expertise. Besides the Administrative Core, these cores include a Clinical Core led by Dr. Lawrence Honig, a ‘Data Management and Statistical’ Core led by Dr. Howard Andrews, a Neuropathology Core led by Dr. Andrew Teich, a Biomarker Core led by Dr. Adam Brickman, a Genetics Core led by Dr. Christiane Reitz, a Neuroimmunology Core led by Dr. Phillip De Jager, an ‘Outreach, Retention, and Engagement’ Core led by Dr. William (Ted) Huey, and a ‘Research Education’ Module led by Dr. James Noble.

总体项目概要/摘要 这是哥伦比亚大学 P30 ADRC 的新申请，延续了我们之前的传统 P50 ADRC 自 1989 年以来一直在哥伦比亚设立。以我们之前的成就为基础，总体目标 新 ADRC 的宗旨是支持和促进阿尔茨海默病 (AD) 及相关疾病的前沿研究 疾病，无论是在我们广阔的校园内，还是在全球范围内与其他机构和国家联盟合作。 在此目标中，中心将有一个更有针对性的主题。 AD 发病机制中涉及的途径是经过内部审议、与我们的讨论后决定的 外部咨询委员会成员以及 NIH 项目官员在整个提案中进行了审查。 相信这个广泛的主题有很多优点，它将通过更好地服务我们来加强总体目标。 当地基础、转化和临床研究人员社区；并将产生新的工具和资源 此外，我们将与其他机构、联盟和组织共享该主题，让每个核心能够 既有与其他 ADRC 和财团协调一致的总体目标，也有出现的主题指导目标 如下所述，该主题将使核心能够在以下领域协同合作。 创建与临床现象学、神经病理学、神经影像学和 AD 的基因组学。 自 30 年前成立以来，哥伦比亚 ADRC 已为以下领域建立了完善的基础设施： 研究，促进跨学科合作，建立丰富的培训环境，促进 与此同时，该中心已成为更加全球化的活动的积极参与者。 网络由其他机构、国家财团和社区组织组成。 在 P50 ADRC 的周期中，该中心已经实现了大部分目标，例如， 其科学发现以及入组和活跃患者的高排名。 在这个新的 P30 ADRC 提案中，我们将在这些先前成就的基础上继续前进，并且 将受到两个总体目标的推动，第一个目标是像之前的周期一样继续促进所有研究。 关于 AD 和相关疾病，而第二个目标是支持该主题，我们建议实现这些目标。 通过我们集成良好的核心，共同建立一个基础设施，生成一系列丰富的 除了管理核心之外，这些核心还包括临床核心。 由劳伦斯·霍尼格 (Lawrence Honig) 博士领导，这是一个“数据管理和统计”核心，由霍华德·安德鲁斯 (Howard Andrews) 博士领导，他是 神经病理学核心由 Andrew Teich 博士领导，生物标记核心由 Adam Brickman 博士领导，遗传学核心 由 Christiane Reitz 博士领导，神经免疫学核心由 Phillip De Jager 博士领导，“外展、保留和 由 William (Ted) Huey 博士领导的“参与”核心模块，以及由 James Noble 博士领导的“研究教育”模块。